Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases - Eli Lilly and Co (NYSE:LLY), Novo Nordisk (NYSE:NVO)

Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases - Eli Lilly and Co (NYSE:LLY), Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) sharply increased its U.S. advertising spend on its blockbuster GLP-1 drugs Wegovy and Ozempic in 2025, outpacing rival Eli Lilly and Co (NYSE:LLY) as competition for market share in the obesity and diabetes space intensified, according to data reviewed by Reuters. Citing data from advertising tracking firm MediaRadar, Reuters noted that Novo Nordisk spent an estimated $316 million promoting Wegovy and $169 million on…